Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature

Monti, Martina; Lunardini, Susanna; Magli, Igino Andrea; Campi, Riccardo; Primiceri, Giulia; Berardinelli, Francesco; Terracciano, Daniela; Lucarelli, Giuseppe; Schips, Luigi; Ferro, Matteo; Marchioni, Michele

doi:10.3390/biomedicines10061287

Cited by 12 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-155 was associated with expanding the MDSCs pool and resistance to treatment with immune checkpoint inhibitors in melanoma patients [ 68 ]. Similarly, in renal cell carcinoma, high expressions of miR-155 were detected in the non-responding patients to CII [ 102 ]. There were no available studies demonstrating the side effects of immune checkpoint immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-155 and Disease-Related Immunohistochemical Parameters in Cutaneous Melanoma

et al. 2023

View full text Add to dashboard Cite

Cutaneous melanoma is a severe and life-threatening form of skin cancer with growing incidences. While novel interventions have improved prognoses for these patients, early diagnosis of targeted treatment remains the most effective approach. MicroRNAs have grown to good use as potential biomarkers for early detection and as targets for treatment. miR-155 is well-studied for its role in tumor cell survival and proliferation in various tissues, although its role in melanoma remains controversial. In silico data analysis was performed in the dbDEMC v.3 to identify differentially expressed miRNA. We validated gene targets in melanoma using TarBase v8.0 and miRPath v3.0 and determined protein-protein interactions of the target genes. One hundred forty patients (age range 21–90 years) with cutaneous melanoma who underwent resection were included. Molecular assessment using Real-Time RT-qPCR, clinicopathological associations, and a literature review for the different roles of miR-155 in melanoma were performed. Analysis of the dbDEMC reveals controversial findings. While there is evidence of upregulation of miR-155 in primary and metastatic melanoma samples, others suggest decreased expression in later-stage melanoma and cases with brain metastasis. miR-155 has been overexpressed in prior cases of melanoma and precancerous lesions, and it was found to be dysregulated when compared to benign nevi. While miR-155 expression was associated with favorable outcomes in some studies, others showed an association with metastasis. Patients with high levels of miR-155 also noted reduction after receiving anti-PD-1 treatment, correlated with more prolonged overall survival. In our patient’s cohort, 22.9% relapsed during treatment, and 45% developed recurrence, associated with factors such as lymph node infiltration, high mitotic index, and positive staining for CD117. Although overall analysis revealed miR-155 downregulation in melanoma specimens compared to non-cancer tissues, increased expression of miR-155 was associated with cases of superficial spreading melanoma subtype (p = 0.005) and any melanoma with a high mitotic rate (p = 0.010). The analysis did not identify optimum cutoff values to predict relapse, recurrence, or mortality. In conclusion, miR-155 could have, in part, a potential prognostic utility in cutaneous melanoma. Further mechanistic studies are required to unravel the multifunctional role of miR-155 in melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-155 and Disease-Related Immunohistochemical Parameters in Cutaneous Melanoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The microRNAs (miRNAs) are a class of noncoding RNAs that can bind to the 3 untranslated region (3 UTR) of target gene transcripts to inhibit translation or reduce the stability of messenger RNA (mRNA) [183].…”

Section: Arginine and Mir-34a-5p/ass1 Axismentioning

confidence: 99%

Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets

Meo

Lasorsa

Rutigliano

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most frequent histological kidney cancer subtype. Over the last decade, significant progress has been made in identifying the genetic and metabolic alterations driving ccRCC development. In particular, an integrated approach using transcriptomics, metabolomics, and lipidomics has led to a better understanding of ccRCC as a metabolic disease. The metabolic profiling of this cancer could help define and predict its behavior in terms of aggressiveness, prognosis, and therapeutic responsiveness, and would be an innovative strategy for choosing the optimal therapy for a specific patient. This review article describes the current state-of-the-art in research on ccRCC metabolic pathways and potential therapeutic applications. In addition, the clinical implication of pharmacometabolomic intervention is analyzed, which represents a new field for novel stage-related and patient-tailored strategies according to the specific susceptibility to new classes of drugs.

show abstract

“…Other mechanisms of resistance described for TKI include the metabolism adaptation of tumour cells to hypoxia, vascular co-option, epithelial-mesenchymal transition, lysosomal sequestration of the drug, epigenetic modification of histone protein and overexpression of PD-L1 [ 58 , 59 ]. Emerging evidence indicates that non-coding RNA such as micro RNAs (miRNA) or long non-coding RNAs (LncRNA) act as modulators of angiogenesis but not only and are involved in TKI resistance [ 60 , 61 , 62 , 63 ]. It might provide novel clinical markers and therapeutical targets for ccRCC patients, but due to their complex role and few data in ccRCC patients, at least for lncRNA, they will not be discussed further in this review.…”

Section: Angiogenesis In Renal Cancermentioning

confidence: 99%

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies

Guillaume

Auvray

Vano

et al. 2022

Cancers

View full text Add to dashboard Cite

Due to the aberrant hypervascularization and the high immune infiltration of renal tumours, current therapeutic regimens of renal cell carcinoma (RCC) target angiogenic or immunosuppressive pathways or both. Tumour angiogenesis plays an essential role in tumour growth and immunosuppression. Indeed, the aberrant vasculature promotes hypoxia and can also exert immunosuppressive functions. In addition, pro-angiogenic factors, including VEGF-A, have an immunosuppressive action on immune cells. Despite the progress of treatments in RCC, there are still non responders or acquired resistance. Currently, no biomarkers are used in clinical practice to guide the choice between the different available treatments. Considering the role of angiogenesis in RCC, angiogenesis-related markers are interesting candidates. They have been studied in the response to antiangiogenic drugs (AA) and show interest in predicting the response. They have been less studied in immunotherapy alone or combined with AA. In this review, we will discuss the role of angiogenesis in tumour growth and immune escape and the place of angiogenesis-targeted biomarkers to predict response to current therapies in RCC.

show abstract

Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature

Cited by 12 publications

References 48 publications

MicroRNA-155 and Disease-Related Immunohistochemical Parameters in Cutaneous Melanoma

MicroRNA-155 and Disease-Related Immunohistochemical Parameters in Cutaneous Melanoma

Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies

Contact Info

Product

Resources

About